New and Emerging Pharmacologic Therapies for Type 2 Diabetes, Dyslipidemia, and Obesity

Abstract Background Type 2 diabetes, dyslipidemia, and obesity continue to be common disorders that many clinicians and patients struggle to control. There are likely numerous reasons for poor control of these diseases, including medication efficacy and adverse effects, access to medications and hea...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical therapeutics 2013, Vol.35 (1), p.A3-A17
Hauptverfasser:	Taylor, James R., PharmD, CDE, Dietrich, Eric, PharmD, BCPS, Powell, Jason G., PharmD
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-Obesity Agents - adverse effects Anti-Obesity Agents - economics Anti-Obesity Agents - therapeutic use canagliflozin Cholesterol Clinical trials Cost-Benefit Analysis dapagliflozin Diabetes Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - economics Drug Costs Drug dosages dyslipidemia Dyslipidemias - diagnosis Dyslipidemias - drug therapy Dyslipidemias - economics exenatide extended-release Gastrointestinal surgery Glucose Humans Hypoglycemic Agents - adverse effects Hypoglycemic Agents - economics Hypoglycemic Agents - therapeutic use Hypolipidemic Agents - adverse effects Hypolipidemic Agents - economics Hypolipidemic Agents - therapeutic use Icosapent ethyl Internal Medicine Medical Education Mortality Obesity Obesity - diagnosis Obesity - drug therapy Obesity - economics Patients Studies Treatment Outcome Triglycerides Weight control
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!